164 related articles for article (PubMed ID: 36129146)
21. A truncating CLDN9 variant is associated with autosomal recessive nonsyndromic hearing loss.
Sineni CJ; Yildirim-Baylan M; Guo S; Camarena V; Wang G; Tokgoz-Yilmaz S; Duman D; Bademci G; Tekin M
Hum Genet; 2019 Oct; 138(10):1071-1075. PubMed ID: 31175426
[TBL] [Abstract][Full Text] [Related]
22. Claudins as diagnostic and prognostic markers in gynecological cancer.
Szabó I; Kiss A; Schaff Z; Sobel G
Histol Histopathol; 2009 Dec; 24(12):1607-15. PubMed ID: 19795358
[TBL] [Abstract][Full Text] [Related]
23. Variants of human CLDN9 cause mild to profound hearing loss.
Ramzan M; Philippe C; Belyantseva IA; Nakano Y; Fenollar-Ferrer C; Tona R; Yousaf R; Basheer R; Imtiaz A; Faridi R; Munir Z; Idrees H; Salman M; Nambot S; Vitobello A; Kartti S; Zarrik O; Witmer PD; Sobreria N; Ibrahimi A; Banfi B; Moutton S; Friedman TB; Naz S
Hum Mutat; 2021 Oct; 42(10):1321-1335. PubMed ID: 34265170
[TBL] [Abstract][Full Text] [Related]
24. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.
Zheng A; Yuan F; Li Y; Zhu F; Hou P; Li J; Song X; Ding M; Deng H
J Virol; 2007 Nov; 81(22):12465-71. PubMed ID: 17804490
[TBL] [Abstract][Full Text] [Related]
25. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
Watari H; Xiong Y; Hassan MK; Sakuragi N
Gynecol Oncol; 2009 Jan; 112(1):229-34. PubMed ID: 19007976
[TBL] [Abstract][Full Text] [Related]
26. LRG1 is an independent prognostic factor for endometrial carcinoma.
Wen SY; Zhang LN; Yang XM; Zhang YL; Ma L; Ge QL; Jiang SH; Zhu XL; Xu W; Ding WJ; Yang BQ; Zhang ZG; Teng YC
Tumour Biol; 2014 Jul; 35(7):7125-33. PubMed ID: 24760273
[TBL] [Abstract][Full Text] [Related]
27. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Fonnes T; Berg HF; Bredholt T; Edqvist PD; Sortland K; Berg A; Salvesen HB; Akslen LA; Werner HMJ; Trovik J; Tangen IL; Krakstad C
Gynecol Oncol; 2018 Jan; 148(1):197-203. PubMed ID: 29096882
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer.
Iravani O; Yip GW; Thike AA; Chua PJ; Jane Scully O; Tan PH; Bay BH
J Clin Pathol; 2016 Oct; 69(10):878-83. PubMed ID: 26926102
[TBL] [Abstract][Full Text] [Related]
29. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
30. Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma.
Liu NT; Perng CL; Chou YC; Ko PS; Lin YJ; Lin YC; Chang CC; Wang YC; Shang HS; Chao TK
PLoS One; 2021; 16(11):e0259330. PubMed ID: 34731191
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac.
Liu Y; Jin X; Li Y; Ruan Y; Lu Y; Yang M; Lin D; Song P; Guo Y; Zhao S; Dong B; Xie Y; Dang Q; Quan C
J Exp Clin Cancer Res; 2016 Jul; 35(1):120. PubMed ID: 27461117
[TBL] [Abstract][Full Text] [Related]
32. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
[TBL] [Abstract][Full Text] [Related]
33. [High expression of MMP20 may be a potential prognostic factor for poor outcomes of patients with endometrial carcinoma].
Zhao Q; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1239-1244. PubMed ID: 30377136
[TBL] [Abstract][Full Text] [Related]
34. Elevated expression of RIT1 correlates with poor prognosis in endometrial cancer.
Xu F; Sun S; Yan S; Guo H; Dai M; Teng Y
Int J Clin Exp Pathol; 2015; 8(9):10315-24. PubMed ID: 26617739
[TBL] [Abstract][Full Text] [Related]
35. Identification and Function Analysis of a Five-Long Noncoding RNA Prognostic Signature for Endometrial Cancer Patients.
Tang H; Wu Z; Zhang Y; Xia T; Liu D; Cai J; Ye Q
DNA Cell Biol; 2019 Dec; 38(12):1480-1498. PubMed ID: 31539276
[TBL] [Abstract][Full Text] [Related]
36. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
37. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
38. Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer.
Kohmoto T; Masuda K; Shoda K; Takahashi R; Ujiro S; Tange S; Ichikawa D; Otsuji E; Imoto I
Gastric Cancer; 2020 May; 23(3):403-417. PubMed ID: 31654186
[TBL] [Abstract][Full Text] [Related]
39. GABPA Expression in Endometrial Carcinoma: A Prognostic Marker.
Ma X; Lin Q; Cui G; Zhao J; Wei X; Li R; Mao H; Ma Y; Liu P; Pang Y
Dis Markers; 2021; 2021():5552614. PubMed ID: 34306255
[TBL] [Abstract][Full Text] [Related]
40. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
Konecny GE; Agarwal R; Keeney GA; Winterhoff B; Jones MB; Mariani A; Riehle D; Neuper C; Dowdy SC; Wang HJ; Morin PJ; Podratz KC
Gynecol Oncol; 2008 May; 109(2):263-9. PubMed ID: 18313739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
